Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines.
Hepatology
; 78(5): 1625-1653, 2023 11 01.
Article
en En
| MEDLINE
| ID: mdl-36626642
ABSTRACT
Liver fibrosis is the result of sustained chronic liver injury and inflammation leading to hepatocyte cell death followed by the formation of fibrous scars, which is the hallmark of NASH and alcoholic steatohepatitis and can lead to cirrhosis, HCC, and liver failure. Although progress has been made in understanding the pathogenesis and clinical consequences of hepatic fibrosis, therapeutic strategies for this disease are limited. Preclinical studies suggest that peroxisome proliferator-activated receptor alpha plays an important role in preventing the development of liver fibrosis by activating genes involved in detoxifying lipotoxicity and toxins, transrepressing genes involved in inflammation, and inhibiting activation of hepatic stellate cells. Given the robust preclinical data, several peroxisome proliferator-activated receptor alpha agonists have been tested in clinical trials for liver fibrosis. Here, we provide an update on recent progress in understanding the mechanisms by which peroxisome proliferator-activated receptor alpha prevents fibrosis and discuss the potential of targeting PPARα for the development of antifibrotic treatments.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
PPAR alfa
/
Cirrosis Hepática
Límite:
Humans
Idioma:
En
Año:
2023
Tipo del documento:
Article